echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Fotivda milestone 5-year follow-up data: efficacy beats Nexavar!

    Fotivda milestone 5-year follow-up data: efficacy beats Nexavar!

    • Last Update: 2022-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    AVEO Oncology recently announced new long-term results from the Phase 3 TIVO-3 study of the targeted anticancer drug Fotivda (tivozanib) in advanced renal cell carcinoma (RCC) at the 2022 American Society of Clinical Oncology Symposium on Genitourinary Cancers (ASCO GU).


    Fotivda, an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), was approved by the U.


    In particular, Fotivda is the first treatment approved for the treatment of adults with relapsed or refractory advanced RCC who have received 2 or more prior systemic regimens


    TIVO-3 is a randomized, active-controlled, multicenter, open-label study in 351 patients with highly refractory advanced or metastatic RCC evaluating Fotivda versus Bayer's targeted cancer drug Nexavar (Nexavar, Generic name: sorafenib, sorafenib) efficacy and safety


    Previously published results showed: (1) Compared with the Nexavar treatment group, the Fotivda treatment group increased the median progression-free survival (PFS) by 44% (5.


    The milestone 5-year follow-up data presented at the meeting showed that the investigators' assessment of PFS was consistent with the independent review committee's findings, with a consistently higher rate of progression-free survival (PFS) in the Fotivda arm compared to the Nexavar arm, with 3-year and 12% vs 2% and 8% vs 0% at 4 years, respectively


    In addition, long-term OS was also analyzed at the meeting, which continued to show a non-significant trend (HR=0.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.